Biomarker-based Multidisciplinary Team (Bio-MDT) Approach to Personalized Microbial-targeted Treatment of Pouchitis and Crohn's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-11

Study Completion Date

2023-06-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBD) currently affecting over 5 million patients globally, mostly young adults. These conditions are often debilitating, disabling and may markedly affect patient's quality of life. Despite important advances in research, the pathogenesis of IBD remains obscure, the incidence-rising, the condition - incurable, and drugs have a modest effect. The common denominator may be environmental factors, specifically diet and the microbiome, which remain a fundamental unmet need in IBD care as high quality randomized trials and mechanistic research are limited. Up to a quarter of patients with UC may undergo complete large bowel resection due to disease complications. In order to preserve bowel continuity, this surgery includes a restorative part with creation of a reservoir ("pouch") from normal small bowel instead of the resected rectum. The majority of these patients develop small intestinal inflammation in the previously normal small bowel creating the pouch ("pouchitis").

Based on our results from previous studies, we hypothesized that personalized antibiotics and dietary interventions will modify microbial composition and result in significantly improved outcomes, specifically resolution of inflammation and prolonged remission rates in patients with a pouch.

Aims:

1. Compare the effect of two antibiotic treatments on clinical, inflammatory and microbiological outcomes of patients with pouch inflammation.
2. Evaluate the effect of combined microbiome-targeted antibiotic and dietary intervention as treatment and prevention strategy in patients after pouch surgery.
3. Evaluate the effect of a microbiome-targeted dietary intervention as prevention strategy in patients after pouch surgery.
4. Identify predictors for response to specific antibiotic and dietary interventions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Decoding Personalized Nutritional, Microbiome and Host Patterns Impacting Clinical and Prognostic Features in Crohn's Disease

NCT04283864

Crohn Disease

RECRUITING

Advanced Therapy Registry of IBD Patients

NCT04998084

Crohn Disease Ulcerative Colitis Pouchitis

UNKNOWN

Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease

NCT06494826

Crohn Disease

RECRUITING

Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases

NCT03841045

Colitis, Ulcerative Crohn Disease

UNKNOWN

The Effect of Intestinal Microbiota Transplantation for Inflammatory Bowel Diseases

NCT03426683

Inflammatory Bowel Disease(IBD)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All patients will undergo comprehensive screening by the bio-MDT.

Aim 1: Antibiotic treatment- (patients with active disease) will be randomized to receive a prescription for one of two antibiotic regimens.

1. Ciprofloxacin + metronidazole
2. Doxycycline+ metronidazole

Aim 2: Combination therapy ( Antibiotics+diet) After arm 1 recruitment completion, a favorable antibiotic regimen will be determined and recommended in arm 2, in which, patients with active disease will be randomized to

1. Favorable antibiotics + Mediterranean diet (MED)
2. Favorable antibiotics + The Specific Carbohydrate Diet (SCD)

Aim 3: Nutritional prevention-

Patients in clinical remission will be recruited to a dietary prevention study and be allocated to one of three groups:

1. Mediterranean diet (MED)
2. Control- based on the American Dietetic Association recommendations for patients with IBD.
3. Personalized nutrition group- based on prior results from study- NCT02858557

Comprehensive assessment including nutritional, clinical, inflammatory and microbial parameters will be performed at baseline and at weeks 2,3,4,8,26, 52.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antibiotic treatment

Patients with active disease will be randomized and will receive a prescription for one of two antibiotic regimens.

1. Ciprofloxacin 500 mg 2/d + metronidazole 500 mg 2/d for two weeks
2. Doxycycline 100 mg 2/d + metronidazole 500 mg 2/d for two weeks

Group Type OTHER

Arm 1- Antibiotics treatment

Intervention Type OTHER

Patients with active disease will be randomized and will receive a prescription antibiotic regimens

Arm 2- Antibiotics treatment

Intervention Type OTHER

Patients with active disease will be randomized and will receive a prescription antibiotic regimens

Combination therapy (Antibiotics + diet)

1. Favorable antibiotics (according to aim 1) for two weeks + Mediterranean diet (MED) for 8 weeks.
2. Favorable antibiotics (according to aim 1) for two weeks + specific carbohydrate diet (SCD) for 8 weeks.

Group Type OTHER

Arm 1- Combination therapy (Antibiotics + diet)

Intervention Type OTHER

Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).

Arm 2- Combination therapy (Antibiotics + diet)

Intervention Type OTHER

Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).

Nutritional prevention

Patients in clinical remission will be recruited to a dietary prevention study.

1. Mediterranean diet
2. Control- based on the American Dietetic Association recommendations for patients with IBD
3. Personalized nutrition group- based on prior results from study- NCT02858557

Group Type OTHER

Arm 1- Nutritional prevention

Intervention Type OTHER

Patients in clinical remission will be recruited to a dietary prevention study

Arm 2- Nutritional prevention

Intervention Type OTHER

Patients in clinical remission will be recruited to a dietary prevention study

Arm 3- Nutritional prevention

Intervention Type OTHER

Patients in clinical remission will be recruited to a dietary prevention study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arm 1- Antibiotics treatment

Patients with active disease will be randomized and will receive a prescription antibiotic regimens

Intervention Type OTHER

Arm 2- Antibiotics treatment

Patients with active disease will be randomized and will receive a prescription antibiotic regimens

Intervention Type OTHER

Arm 1- Combination therapy (Antibiotics + diet)

Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).

Intervention Type OTHER

Arm 2- Combination therapy (Antibiotics + diet)

Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).

Intervention Type OTHER

Arm 1- Nutritional prevention

Patients in clinical remission will be recruited to a dietary prevention study

Intervention Type OTHER

Arm 2- Nutritional prevention

Patients in clinical remission will be recruited to a dietary prevention study

Intervention Type OTHER

Arm 3- Nutritional prevention

Patients in clinical remission will be recruited to a dietary prevention study

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ciprofloxacin 500 mg 2/d + metronidazole 500 mg 2/d for two weeks Doxycycline 100 mg 2/d + metronidazole 500 mg 2/d for two weeks Favorable antibiotics (according to aim 1) for two weeks + Mediterranean diet (MED) for 8 weeks. Favorable antibiotics (according to aim 1) for two weeks + specific carbohydrate diet (SCD) for 8 weeks. Mediterranean diet Control- based on the American Dietetic Association recommendations for patients with IBD Personalized nutrition group- based on prior results from study- NCT02858557

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients are able and willing to sign an informed consent
2. Patients with UC who underwent pouch surgery and have a functioning pouch
3. Disease activity (PDAI and PGA) according to study arm 1-3 inclusion

Exclusion Criteria

1. Patients with ileostomy
2. Significant comorbidity that precludes the patient from participating according to the physicians' judgment
3. Non-Hebrew readers
4. Pregnant and lactating women

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No